Program
Maraviroc
Also written as “Maraviroc (UK-427,857)”, “maraviroc” and “Maraviroc + Fosamprenavir/ritonavir”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Post-Acute COVID-19 Syndrome · Infections · Arthritis, Rheumatoid, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 220 open or running | phase 4since Apr 23, 2008 | Dec 6, 2004 | none ahead |
| Pfizer | 20 open or running | phase 2since Jan 25, 2007 | Jan 25, 2007 | none ahead |
| HealthBio | 11 open or running | phase 3since May 7, 2025 | May 7, 2025 | Dec 1, 2026phase 3 · NCT06974084 |
| Population Council | 10 open or running | phase 1since Jan 20, 2015 | Jan 20, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Dec 6, 2004.
- Oct 30, 2008Phase 1 study in Healthy VolunteersPfizer · NCT00783484 · 37 enrolled · Belgium
- Nov 12, 2008Phase 2 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT00791700 · 103 enrolled · United States, Brazil, Italy and more
- Jan 12, 2009Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT00821535 · 12 enrolled · Singapore
- Jan 21, 2009Phase 2 study in Human Immunodeficiency Virus-1GlaxoSmithKline · NCT00827112 · 129 enrolled · United States, Germany, Spain
- Jan 22, 2010Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT01056874 · 12 enrolled · Singapore
- Jun 7, 2010Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01140412 · 14 enrolled · Singapore
- Feb 3, 2011Phase 1 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01290211 · 28 enrolled · Belgium
- Mar 22, 2011Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT01327547 · 138 enrolled · United States, Czechia, France and more
- Apr 27, 2011Phase 3 study in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT01345630 · 813 enrolled · United States, Australia, Austria and more
- May 10, 2012Phase 1 study in HealthyGlaxoSmithKline · NCT01597895 · 14 enrolled · Belgium
- Jan 20, 2015Population Council's first study: phase 1 study in Acquired Immunodeficiency SyndromeNew to Population CouncilPopulation Council · NCT02346084 · 19 enrolled · United States
- Jun 16, 2015Phase 1 study in InfectionsGlaxoSmithKline · NCT02480894 · 112 enrolled · United States
- Oct 20, 2015Phase 1 study in Healthy SubjectsGlaxoSmithKline · NCT02625207 · 47 enrolled · United States
- May 7, 2025HealthBio's first study: phase 3 study in Post-Acute COVID-19 SyndromeNew to HealthBioHealthBio · NCT06974084 · 252 planned · United States
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Post-Acute COVID-19 SyndromeHealthBio · NCT06974084
TargetBeta
“A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV)”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule
Other programs on CCR5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| leronlimabrule | CytoDyn | phase 3 | 20 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06974084Post-Acute COVID-19 Syndrome · United States | 3 | Not yet recruiting | HealthBio | Dec 1, 2026 | 252 |
| NCT02625207Healthy Subjects · United States | 1 | Completed | GlaxoSmithKline | Mar 26, 2016 | 47 |
| NCT02480894Infections · United States | 1 | Completed | GlaxoSmithKline | Sep 21, 2015 | 112 |
| NCT02346084Acquired Immunodeficiency Syndrome · United States | 1 | Completed | Population Council | Dec 2015 | 19 |
| NCT01597895Healthy · Belgium | 1 | Completed | GlaxoSmithKline | Aug 2012 | 14 |
| NCT01345630Acquired Immunodeficiency Syndrome · United States, Australia, Austria and more | 3 | Terminated | GlaxoSmithKline | Aug 2013 | 813 |
| NCT01327547HIV Infections · United States, Czechia, France and more | 4 | Completed | GlaxoSmithKline | Apr 23, 2013 | 138 |
| NCT01290211Acquired Immunodeficiency Syndrome · Belgium | 1 | Completed | GlaxoSmithKline | Jun 2011 | 28 |
| NCT01140412Acquired Immunodeficiency Syndrome · Singapore | 1 | Terminated | GlaxoSmithKline | Oct 2010 | 14 |
| NCT01056874HIV Infections · Singapore | 1 | Completed | GlaxoSmithKline | Apr 2010 | 12 |
| NCT00827112Human Immunodeficiency Virus-1 · United States, Germany, Spain | 2 | Completed | GlaxoSmithKline | Jul 2010 | 129 |
| NCT00821535Acquired Immunodeficiency Syndrome · Singapore | 1 | Completed | GlaxoSmithKline | May 2009 | 12 |
| NCT00791700Acquired Immunodeficiency Syndrome · United States, Brazil, Italy and more | 2 | UNKNOWN | GlaxoSmithKline | Apr 14, 2015 | 103 |
| NCT00783484Healthy Volunteers · Belgium | 1 | Completed | Pfizer | May 2009 | 37 |
| NCT00782301Hepatitis B · United States, Canada, Poland | 4 | Withdrawn | GlaxoSmithKline | Feb 2010 | 0 |
| NCT00719823Acquired Immunodeficiency Syndrome | 3 | Withdrawn | GlaxoSmithKline | May 2010 | 0 |
| NCT00717067Acquired Immunodeficiency Syndrome · Germany | 4 | Completed | GlaxoSmithKline | Nov 2008 | 30 |
| NCT00666705Healthy · United States | 4 | Completed | GlaxoSmithKline | Mar 2008 | 18 |
| NCT00643643HIV Infections · Germany, Netherlands, United Kingdom | 2 | Completed | GlaxoSmithKline | Jun 2003 | 41 |
| NCT00634959HIV Infections · United States, Germany, United Kingdom | 2 | Completed | GlaxoSmithKline | 37 | |
| NCT00496782HIV Infections · United States, Canada | 1 | Terminated | GlaxoSmithKline | Oct 2008 | 16 |
| NCT00478231Acquired Immunodeficiency Syndrome · Brazil | 3 | Completed | GlaxoSmithKline | Aug 2010 | 209 |
| NCT00427934Arthritis, Rheumatoid · United States, Australia, Germany and more | 2 | Terminated | Pfizer | Oct 2008 | 128 |
| NCT00426660HIV Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jun 2010 | 1,047 |
| NCT00098722HIV Infections · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2007 | 474 |
| NCT00098293Acquired Immunodeficiency Syndrome · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 2007 | 916 |
How it is read
Names in the registry
- “Maraviroc”, 23 entries
- “Maraviroc (UK-427,857)”, 8 entries
- “maraviroc”, 5 entries
- “Maraviroc + Fosamprenavir/ritonavir”, 4 entries
- “Maraviroc +PF-03716539”, 2 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 10 studies
- HIV Infections, 7 studies
- Post-Acute COVID-19 Syndrome, 1 study
- Infections, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.